Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Paraneoplastic nervous system syndromes

K A Jaeckle1

  • 1Department of Neuro-Oncology, University of Texas M.D. Anderson Cancer Center, Houston 77030, USA.

Current Opinion in Oncology
|May 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Transformation of low grade glioma and correlation with outcome: an NCCTG database analysis.

Journal of neuro-oncology·2010
Same author

Medical Research Council adjuvant trial in high-grade gliomas.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2001
Same author

Response and progression in recurrent malignant glioma.

Neuro-oncology·2001
Same author

Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine.

British journal of cancer·2001
Same author

Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme.

Clinical cancer research : an official journal of the American Association for Cancer Research·2000
Same author

A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors.

Clinical cancer research : an official journal of the American Association for Cancer Research·1999
Same journal

Artificial intelligence-augmented robotic surgery in gynecologic oncology: intraoperative assistance and analytics.

Current opinion in oncology·2026
Same journal

Artificial intelligence in cervical cancer screening and triage: a role-stratified systematic review and bivariate meta-analysis.

Current opinion in oncology·2026
Same journal

Deep learning assisting the surgical management of gynecologic cancers.

Current opinion in oncology·2026
Same journal

Pain management in pancreatic cancer: time to change our strategy!

Current opinion in oncology·2026
Same journal

Systemic radionuclide treatments in gastro-entero-pancreatic neuroendocrine tumours.

Current opinion in oncology·2026
Same journal

5-Fluorouracil at seventy: still attractive but barely understood. A cautionary tale for drug development.

Current opinion in oncology·2026
See all related articles

Paraneoplastic neurologic syndromes (PNS) understanding has advanced, but their autoimmune pathogenesis and effective treatments remain elusive. Future research should explore genetic regulation and novel therapies for better management.

Area of Science:

  • Neurology
  • Immunology
  • Oncology

Background:

  • Paraneoplastic neurologic syndromes (PNS) are a diverse group of disorders.
  • Despite decades of research, their autoimmune pathogenesis is not fully understood.
  • Effective treatments for most PNS are lacking, with few exceptions.

Purpose of the Study:

  • To review recent advancements in understanding PNS.
  • To highlight the challenges in diagnosing and treating these syndromes.
  • To suggest future research directions for improved management.

Main Methods:

  • Review of current literature on paraneoplastic neurologic syndromes.
  • Analysis of progress in clinical delineation, nomenclature, pathogenesis, and antigen characterization.
  • Identification of knowledge gaps and future research priorities.

Related Experiment Videos

Main Results:

  • Progress has been made in defining clinical features, diagnostic criteria, and identifying paraneoplastic antigens.
  • The underlying autoimmune mechanisms and effective therapies for most PNS remain unclear.
  • Opsoclonus-myoclonus ataxia and Lambert-Eaton myasthenic syndromes show some treatment responses.

Conclusions:

  • Further research is crucial to elucidate the genetic and autoimmune basis of PNS.
  • Development of animal models and exploration of non-traditional therapies are needed.
  • A deeper understanding of pathogenesis is key to developing effective management strategies for PNS.